BioMarin Pharmaceuticals BMRN Accounts payable and accrued liabilities related to fixed assets
Accounts payable and accrued liabilities related to fixed assets at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept bmrn:CapitalExpendituresIncurredButNotYetPaidFixedAssets.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to fixed assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to fixed assets?
- BioMarin Pharmaceuticals (BMRN) reported accounts payable and accrued liabilities related to fixed assets of $11.2M in Q1 2026.
- How has BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to fixed assets changed year-over-year?
- BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to fixed assets increased by 150.6% year-over-year, from $4.47M to $11.2M.
- What does accounts payable and accrued liabilities related to fixed assets mean?
- Capital investments in physical assets that have been committed to but not yet paid for in cash.
- How do you interpret accounts payable and accrued liabilities related to fixed assets?
- An increase indicates rising capital investment commitments that will require future cash outflows.
- How does accounts payable and accrued liabilities related to fixed assets compare across companies?
- Common in capital-intensive industries; reflects the timing gap between project execution and payment.